A pill that delivers electrical stimulation to the vagus nerve from inside the stomach was able to trigger the release of appetite-controlling neurohormones, specifically the “hunger hormone” ghrelin. The work, which was described in the April 26, 2023, issue of Science Robotics, could pave the way for treating “metabolic, [gastrointestinal], and neuropsychiatric disorders noninvasively with minimal off-target effects,” the authors wrote in their paper. Read More
The brain is plastic throughout life, but never more so than from birth to young adulthood. It increases its volume by developing dendrites and axons that connect neurons in to each other, forming new pathways to process the information that it will store. Those connections require maintenance. And if a connection is unsuccessful, better to delete it than to keep it. This is known as synaptic pruning and occurs from childhood to the age of 20. Now, a group of scientists from the University of Cambridge and Fudan University has described a neuropsychopathological (NP) factor that explains why inappropriate pruning in adolescence is related to mental health disorders. Read More
Researchers from Idorsia Pharmaceuticals Ltd. presented the discovery of ACT-1002-4391, a novel dual antagonist of the prostanoid EP2 and EP4... Read More
Expres2ion Biotechnologies ApS has presented data on ES2B-C001, a virus-like particle vaccine against HER2 for the treatment of breast cancer... Read More
Several immunotherapeutics for cancer are focused on targeting mesothelin (MSLN), including antibody-drug conjugates (ADCs) with traditional... Read More
Grünenthal Gmbh and King’s College London have entered into a 24-month collaboration to develop microfluidic culture (MFC) models based on human induced pluripotent stem cells (iPSCs) for pain research. Read More
Research at Incyte Corp. has led to the development of pyrazoloquinoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors and reported to be useful for the treatment of cancer, inflammatory and immunological disorders. Read More
Crinetics Pharmaceuticals Inc. has reported parathyroid hormone PTH1 receptor antagonists potentially useful for the treatment of kidney stones, osteoporosis, cardiovascular disorders, cognitive disorders, primary hyperparathyroidism and secondary hyperparathyroidism. Read More
Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase restricted to the hematopoietic compartment that plays a crucial role in cellular proliferation, apoptosis and modulation of the antitumor immune response. In mice, HPK1 deficiency is associated with enhanced immune response, and thus, HPK1 is considered a novel target for cancer immunotherapy. Read More
Leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors have been detailed in a recent Merck Sharp & Dohme Corp. patent and reported to be useful for the treatment of Parkinson’s disease, among others. Read More
Interleukin-13 (IL-13) receptor subunit α2 (IL13RA2), one of the two major receptors for IL-13 is overexpressed in glioblastoma multiforme and other solid tumors and is correlated with poor prognosis. Read More
